S-1 for the treatment of gastrointestinal cancer

Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study

(2017) M. Jin et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase III study of sox (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer.

(2017) Y. S. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated results of the FIRIS study: A phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC).

(2017) H. Baba et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study.

(2017) T. Ioka et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial.

(2017) Y. H. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of preoperative chemotherapy with S-1 (S) and cisplatin (P) followed by D3 gastrectomy for gastric cancer (GC) with extensive lymph node metastasis (ELM): Survival results of JCOG0405.

(2017) T. Yoshikawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study.

(2017) M. Terashima et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated survival results of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC).

(2017) Toshio Otsuji et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL+BV; SOLA) in patients with unresectable metastatic colorectal cancer (mCRC).

(2017) Takeshi Kato et al.   JOURNAL OF CLINICAL ONCOLOGY

Retrospective cohort study on the safety and efficacy of cetuximab for metastatic colorectal cancer patients: The HGCSG0901 study—Analysis of cetuximab refractory.

(2017) Satoshi Yuki et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805).

(2017) Chigusa Morizane et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of bevacizumab on sinusoidal injury in patients receiving oxaliplatin-based chemotherapy and liver damage after massive hepatectomy in rats.

(2017) Mitsuo Shimada et al.   JOURNAL OF CLINICAL ONCOLOGY

Changes in expression levels of excision repair cross-complementing group 1 (ERCC1) and dihydropyrimidine dehydrogenase (DPD) during first-line oxaliplatin-based treatment of advanced metastatic colorectal cancer (mCRC).

(2017) Hideo Baba et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.

(2017) Daisuke Takahari et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy (OGSG 0604).

(2017) Jin Matsuyama et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the gene expressions of thymidylate synthase and dihydropyrimidine dehydrogenase on survival in patients enrolled in the ACTS-GC study.

(2017) Mitsuru Sasako et al.   JOURNAL OF CLINICAL ONCOLOGY

Interaction between intratumoral ERCC1 expression and adjuvant treatment with S-1 on the survival of patients enrolled in the ACTS-GC study.

(2017) Koji Kitada et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial

(2012) I Mochizuki et al.   BRITISH JOURNAL OF CANCER

Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)

(2012) Masato Ozaka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

(2011) Wasaburo Koizumi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

6121 POSTER Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)

(2011) D. Takahari et al.   EUROPEAN JOURNAL OF CANCER

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

(2011) Hiroyuki Narahara et al.   Gastric Cancer

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

(2011) Toshiaki Watanabe et al.   International Journal of Clinical Oncology

A Comparison of Multimodality Treatment: Two and Four Courses of Neoadjuvant Chemotherapy Using S-1/CDDP or S-1/CDDP/Docetaxel Followed by Surgery and S-1 Adjuvant Chemotherapy for Macroscopically Resectable Serosa-positive Gastric Cancer: A Randomized Phase II Trial (COMPASS-D Trial)

(2011) T. Yoshikawa et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer

(2011) H. Ueno et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer

(2011) Mitsuru Sasako et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Multi-Center Study of Triple Therapy with Paclitaxel, S-1 and Cisplatin in Patients with Advanced Gastric Cancer

(2011) H. Iwase et al.   ONCOLOGY

Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

(2011) Yoshito Komatsu et al.   ONCOLOGY

Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results

(2010) S. R. Park et al.   ANNALS OF ONCOLOGY

Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer

(2010) Jin Young Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

(2010) Manabu Shiozawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer

(2010) Kentaro Sudo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer

(2010) Hitoshi Kusaba et al.   CANCER SCIENCE

Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients

(2010) Benjamin Chuah et al.   CANCER SCIENCE

A Comparison of Multimodality Treatment: Two or Four Courses of Paclitaxel plus Cisplatin or S-1 plus Cisplatin Followed by Surgery for Locally Advanced Gastric Cancer, a Randomized Phase II Trial (COMPASS)

(2010) T. Yoshikawa et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

(2010) Jaffer A. Ajani et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

(2010) Kei Muro et al.   LANCET ONCOLOGY

Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer

(2009) D. Y. Zang et al.   ANNALS OF ONCOLOGY

Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer

(2009) W. Koizumi et al.   ANNALS OF ONCOLOGY

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)

(2009) W. Koizumi et al.   ANNALS OF ONCOLOGY

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer

(2009) T Yoshioka et al.   BRITISH JOURNAL OF CANCER

Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer

(2009) Yasushi Sato et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

S-1: a promising new oral fluoropyrimidine derivative

(2009) Muhammad Wasif Saif et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002)

(2009) Taira Kinoshita et al.   Gastric Cancer

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

(2009) Narikazu Boku et al.   LANCET ONCOLOGY

XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center

(2009) F. M. Muggia et al.   MOLECULAR CANCER THERAPEUTICS

Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

(2009) A. Tsunoda et al.   ONCOLOGY

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

(2008) Y Yamada et al.   BRITISH JOURNAL OF CANCER

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study

(2008) Junji Furuse et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

(2008) Chigusa Morizane et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?

(2008) J. L. Yen-Revollo et al.   CLINICAL CANCER RESEARCH

Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines

(2008) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY